MarketVibe - S&P 500 Business Analysis | Business Investing

Discover how Elevance Health evolved from a local Indiana insurer into a global data giant managing the lives of 47 million Americans.

[INTRO]

ALEX: If you live in the U.S., there is a roughly one-in-seven chance that a company you’ve probably never heard of holds the keys to your medical records and your prescription drugs.

JORDAN: How have I not heard of a company that big? Are they new?

ALEX: They aren't new, but they’ve changed their name four times to hide their growing power. We’re talking about Elevance Health, the 20th largest company in America that is quietly moving from paying your doctor bills to actually owning the doctors.

JORDAN: So they aren't just the middleman anymore? They’re the whole stadium. Let’s dig into how they pulled this off.

[CHAPTER 1 - Origin]

ALEX: The story begins in 1944 in Indianapolis with a humble group called Mutual Hospital Insurance. Back then, health insurance was mostly a non-profit, regional affair, but this group eventually became the original Anthem.

JORDAN: Anthem I’ve heard of. The Blue Cross Blue Shield logo is everywhere. But how did a local Indiana group become a national behemoth?

ALEX: Through an absolute acquisition spree. Throughout the 90s, they started gobbling up Blue Cross plans in Kentucky, Ohio, Connecticut, and Maine. They were effectively consolidating the fragmented 'Blues' network under one corporate roof.

JORDAN: And I’m guessing they stopped being a 'charitable' non-profit pretty quickly?

ALEX: Exactly. In 2001, Anthem became the first Blue Cross plan to go public on the stock market. That was the turning point from community service to corporate profit-seeking.

JORDAN: So they went from a local utility to a Wall Street darling. What was the next move?

ALEX: A massive merger in 2004 with a California rival named WellPoint. It was a 16-billion-dollar deal that made them the largest health insurer in the country overnight. For a decade, they went by the name WellPoint, covering over 28 million people.

[CHAPTER 2 - Core Story]

JORDAN: If they were so successful as WellPoint, why the heck are we calling them Elevance now?

ALEX: Because the 2010s were a rollercoaster of PR disasters and failed power grabs. In 2014, they switched their name back to Anthem to capitalize on brand recognition for the new Affordable Care Act marketplaces. But then, the wheels started coming off.

JORDAN: Every time a company this big hits a bump, it’s usually a massive one. What happened?

ALEX: Two things. First, in 2015, they suffered one of the largest data breaches in history. Hackers stole the personal info—including Social Security numbers—of nearly 79 million people. They eventually paid a 115-million-dollar settlement, the largest ever at the time.

JORDAN: Seventy-nine million? That’s almost a quarter of the U.S. population. Did that kill their growth?

ALEX: Not even close. While they were dealing with the hack, they tried to buy their rival, Cigna, for a staggering 54 billion dollars. They wanted to create a healthcare monopoly.

JORDAN: I’m guessing the government had some thoughts about a health insurance monopoly.

ALEX: They did. The Department of Justice sued to block it, arguing it would kill competition and drive up prices. A federal court agreed and killed the deal in 2017. It was a massive, high-profile failure that forced Anthem to rethink its entire strategy.

JORDAN: So if they couldn't get bigger by buying competitors, how did they grow?

ALEX: They stopped just being a 'payer'—someone who just cuts checks for doctors—and became a 'player.' They launched their own pharmacy manager, IngenioRx, and started buying up clinics and data analytics firms.

JORDAN: And that’s where the name Elevance comes in?

ALEX: Exactly. In June 2022, they officially rebranded to Elevance Health. The CEO, Gail Boudreaux, wanted a name that sounded more like a tech-driven 'integrated health company' and less like a boring old insurance firm.

[CHAPTER 3 - Why It Matters]

JORDAN: Okay, but for me as a patient, does it actually matter if they call themselves Anthem or Elevance or 'Super-Health-Data-Corp'?

ALEX: It matters because of how you get care. Under their new 'Carelon' brand, they now control the pharmacy benefits, the clinical research, and even some of the primary care offices. They aren't just judging whether your claim is valid; they are managing the entire 'supply chain' of your health.

JORDAN: It sounds efficient, but also a little scary. If they own the insurance and the doctor, who is looking out for the patient's wallet?

ALEX: That’s the trillion-dollar tension. Elevance argues that by owning everything, they can use data to predict illnesses and lower costs through 'value-based care.' Critics, however, point to things like 'prior authorization'—where they can delay or deny procedures to save money.

JORDAN: So their size gives them incredible power to negotiate drug prices, but also incredible power to decide what care you're allowed to have.

ALEX: Precisely. They are currently the 20th largest company on the Fortune 500, pulling in over 150 billion dollars in revenue. They are a titan of the American economy that most people only interact with when they're looking at a plastic card in their wallet.

[OUTRO]

JORDAN: This is a lot to take in. What’s the one thing to remember about Elevance Health?

ALEX: Remember that Elevance is the ultimate symbol of the modern healthcare 'stack'—a company that has moved beyond just paying for your insurance to actively managing nearly every aspect of your medical life through data.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Discover how a 1792 marine insurer evolved into a modern healthcare giant, navigating 230 years of history, massive mergers, and high-tech controversies.

[INTRO]

ALEX: Most people know Cigna as the company that handles their health insurance, but here is a wild fact: their history doesn't start with doctors or hospitals. It starts with pirates.

JORDAN: Pirates? Are you telling me my dental plan has a secret history on the high seas?

ALEX: Literally. Their oldest ancestor was founded in 1792 at Independence Hall, and their first policies covered merchant ships against 'pirates, rovers, and thieves.'

JORDAN: Okay, that is a hell of a pivot. How do you go from fighting 'Blackbeard' to managing pharmacy benefits for millions of Americans?

ALEX: It’s a 230-year journey of radical evolution, and it tells the entire story of how American business—and healthcare—became the giants they are today.

[CHAPTER 1 - Origin]

ALEX: To understand Cigna, you have to look at two different companies that finally slammed together in 1982. First, you have the Insurance Company of North America, or INA. They were the first stock insurance company in the U.S., founded right after the Revolution.

JORDAN: So they weren't just covering ships; they were basically betting on the survival of the new country.

ALEX: Exactly. And they were good at it. They survived the Great Chicago Fire in 1871 and the 1906 San Francisco earthquake, paying out millions when other companies just folded. Then, on the other side, you have Connecticut General Life Insurance, which started in 1865.

JORDAN: Let me guess, they were the 'health' half of the equation?

ALEX: Eventually, yes. While INA was focused on property and disasters, Connecticut General—or CG—focused on life insurance and employee benefits. By the mid-20th century, Hartford, Connecticut, was the insurance capital of the world, and CG was a major player there.

JORDAN: So you’ve got the old-school Philadelphia giants and the Hartford life insurance pros. What brought them together?

ALEX: Survival and scale. In 1982, they merged to create a 'financial supermarket.' They even took the 'C' from CG and the 'INA' from the other guy to create the name 'Cigna.'

[CHAPTER 2 - Core Story]

ALEX: For a while, Cigna tried to do everything—home insurance, car insurance, life insurance. But in 1999, they made a massive decision. They sold off their entire property and casualty business to ACE Limited.

JORDAN: Wait, they walked away from their 200-year history of covering fires and earthquakes?

ALEX: They did. They bet the entire house on healthcare. Under CEO David Cordani, who took over in 2009, they stopped being just an insurance middleman and started trying to own the entire pipeline.

JORDAN: What does that actually look like in practice?

ALEX: It looks like a $67 billion shopping spree. In 2018, Cigna bought Express Scripts, which is a Pharmacy Benefit Manager, or PBM.

JORDAN: I’ve heard that term in the news, but I never know what it actually is. It sounds like corporate jargon.

ALEX: Think of a PBM as the invisible hand behind the pharmacy counter. They negotiate the prices of drugs with manufacturers and decide which ones your insurance will actually cover.

JORDAN: So by buying them, Cigna isn't just paying the bills anymore. They are the ones deciding how much the drug costs and whether you’re allowed to have it.

ALEX: Precisely. It’s called vertical integration. They also launched a brand called Evernorth to house all these services. It’s why Cigna consistently sits in the top 15 of the Fortune 500, with annual revenue pushing $200 billion.

JORDAN: That is an insane amount of money. But if they’re making that much, why does it still feel like a tooth-and-nail fight every time I try to get a claim approved?

ALEX: That’s where the story gets darker. In 2023, an investigation by ProPublica revealed a system Cigna used called 'PXDX.' It’s an algorithm that allowed medical directors to review and deny claims in batches.

JORDAN: Like, they weren't even looking at the individual files?

ALEX: According to the reports, one doctor denied 60,000 claims in a single month. On average, they spent about 1.2 seconds on each case.

JORDAN: One point two seconds? You can’t even read a patient's name in that time, let alone decide if they need an MRI.

ALEX: Cigna defended it, saying it was a way to speed up the process for claims that didn't meet certain criteria, but the outcry was massive. It highlighted the core tension: a company’s fiduciary duty to its shareholders versus its medical duty to its members.

[CHAPTER 3 - Why It Matters]

JORDAN: It feels like Cigna is less of an insurance company now and more of a data and logistics company that happens to deal in human health.

ALEX: That is exactly how they want to be seen. With Evernorth, they are betting that big data and predictive analytics can manage health more efficiently than humans ever could. They use your pharmacy data and medical claims to predict when you might get sick or stop taking your meds.

JORDAN: It’s 'Minority Report' but for your blood pressure.

ALEX: In a way, yes. Their impact today is massive because they aren't just one player; they are the architect of the system. They spend millions every year lobbying in D.C. to shape the laws that govern how we pay for care.

JORDAN: So they aren't just playing the game; they're writing the rulebook and owning the stadium.

ALEX: And they’re doing it with a 230-year-old pedigree. They’ve survived the founding of the country, the burning of Chicago, and the digital revolution. They are masters of the pivot.

[OUTRO]

JORDAN: We covered a lot of ground today. What’s the one thing to remember about Cigna?

ALEX: Cigna is no longer just an insurance company; it is a vertically integrated health services titan that uses massive data and corporate scale to control both the cost and the delivery of American healthcare.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Discover how a network of non-profits became Elevance Health, the world's seventh-largest healthcare company, through mergers, massive data breaches, and rebranding.

[INTRO]

ALEX: Most people think of their health insurance company as a faceless entity that just pays the bills, but Elevance Health actually manages the lives of nearly 47 million people.

JORDAN: 47 million? That is roughly one in seven Americans. I’ve probably heard of them, but the name doesn't ring a bell.

ALEX: That is because until 2022, you knew them as Anthem. They didn't just change their name; they’re trying to move from being the person who pays for your surgery to the person who runs the clinic, the pharmacy, and the mental health app.

JORDAN: So they aren't just the middleman anymore? They want to be the whole system. That sounds like a massive power play.

[CHAPTER 1 - Origin]

ALEX: It really is. To understand how they got here, you have to go back to 1946. This giant actually started as a patchwork of small, regional, non-profit Blue Cross and Blue Shield plans.

JORDAN: Wait, non-profits? How does a local non-profit from Indiana end up 20th on the Fortune 500?

ALEX: Through a relentless, decades-long spree of mergers and acquisitions. The big turning point was 1984, when the Indiana Blue Cross and Blue Shield plans merged to form Anthem.

JORDAN: I’m guessing they didn't stay in Indiana for long.

ALEX: Not at all. They started gobbling up other regional plans across the country. In 1999, they officially went public, trading their non-profit status for Wall Street capital.

JORDAN: And that’s when the 'for-profit' engine really kicked into gear, I assume.

ALEX: Exactly. In 2004, they pulled off a 16-billion-dollar merger with WellPoint Health Networks. This transformed them into the largest health benefits company in the U.S. overnight. They were no longer a local player; they were a titan.

[CHAPTER 2 - Core Story]

JORDAN: So they own the market, they have the scale—is it all smooth sailing from there?

ALEX: Far from it. Once you get that big, the target on your back gets huge. In February 2015, they got hit by one of the largest healthcare data breaches in history.

JORDAN: Oh, I remember that. How many people were affected?

ALEX: Nearly 79 million people had their sensitive data exposed, including Social Security numbers. It cost them a record-setting 115-million-dollar settlement and a massive hit to their reputation.

JORDAN: That’s a nightmare. Did that slow down their expansion plans?

ALEX: Well, they tried to double down instead. Right after the breach, they launched an audacious 54-billion-dollar bid to buy their rival, Cigna.

JORDAN: 54 billion? That would have made them an absolute monopoly in some places.

ALEX: That is exactly what the Department of Justice thought. The DOJ sued to block the deal, arguing it would crush competition and hike prices for everyone.

JORDAN: Did they win? Or did the mega-merger go through?

ALEX: The government won. A federal court blocked the deal in 2017. It was a massive defeat for the CEO at the time, Joseph Swedish, and it forced the company to completely rethink its strategy.

JORDAN: So if they can't buy their competitors, what do they do? Just sit on their cash?

ALEX: No, they pivot. They brought in a new CEO, Gail Boudreaux, who is basically the architect of the modern company. She realized if they couldn't get bigger *outwardly* by buying other insurers, they had to grow *inwardly*.

JORDAN: What does 'growing inwardly' actually look like in healthcare?

ALEX: It means vertical integration. Instead of just being 'Anthem the Insurer,' they rebranded to 'Elevance Health' in 2022. They launched a new division called Carelon to handle pharmacy benefits, behavioral health, and even home care.

JORDAN: So instead of paying a third party for my prescription, I’m paying Elevance's own pharmacy company? They're paying themselves.

ALEX: Precisely. They call it 'whole-person health,' but critics see it as a way to capture every single dollar spent on a patient’s care, from the insurance premium to the physical therapy session.

[CHAPTER 3 - Why It Matters]

JORDAN: This feels like a huge shift for the average patient. Does this actually make healthcare better, or just more profitable for them?

ALEX: That is the multi-billion dollar question. Elevance argues that by owning the whole chain, they can coordinate care better and focus on things like mental health and social factors that traditional insurance ignores.

JORDAN: But I’m guessing there’s a 'but' coming.

ALEX: There is. Critics point to the fact that their government-funded business—Medicare and Medicaid—is now their biggest revenue driver. In 2023, that segment brought in 86 billion dollars, more than their commercial insurance for employers.

JORDAN: So they are essentially a massive engine fueled by taxpayer money.

ALEX: Effectively, yes. And they’ve faced heavy scrutiny over claim denials. A 2019 report suggested they were denying claims at a high rate initially, only to overturn them if the patient was persistent enough to appeal.

JORDAN: That sounds like a war of attrition against their own members.

ALEX: It’s a tension that isn't going away. They are a for-profit company with a fiduciary duty to shareholders, but they are also the primary gatekeeper of health for 47 million people. When they decide what is 'medically necessary,' it affects lives.

JORDAN: It’s wild to think this all started as a few non-profits in the 40s. Now they have 100,000 employees and a finger in every part of the medical pie.

ALEX: They are the ultimate example of how American healthcare has become an integrated, high-tech, corporate industry.

[OUTRO]

JORDAN: So, what’s the one thing we should remember about Elevance Health?

ALEX: Elevance Health is the perfect case study of how the American health insurer evolved from a simple bill-payer into a vertically integrated giant that manages every aspect of your well-being for profit.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Discover how Moderna transformed from a secretive startup into a global powerhouse by treating biological code like software to fight COVID-19 and cancer.

[INTRO]

ALEX: On January 11, 2020, the genetic code for a new virus was published online. Just forty-eight hours later, a company in Massachusetts had already designed a vaccine to stop it.

JORDAN: Wait, forty-eight hours? Most vaccines take a decade of trial and error in a lab. How do you finish the design phase over a single weekend?

ALEX: Because Moderna doesn't think of themselves as a traditional drug company. They see themselves as a software company. They didn’t need the physical virus; they just needed the digital code to rewrite it.

JORDAN: That sounds like science fiction. But today we’re talking about a company that went from a zero-product "mystery startup" to a household name practically overnight.

[CHAPTER 1 - Origin]

ALEX: The story starts in 2010 in Cambridge, Massachusetts. A group of scientific heavyweights, including MIT legend Robert Langer and venture capitalist Noubar Afeyan, founded a company called Moderna.

JORDAN: "Moderna." Sounds futuristic. Where does the name actually come from?

ALEX: It’s a portmanteau: Modified RNA. That’s the "software" I mentioned. Their whole premise was based on research by Derrick Rossi, who figured out how to use messenger RNA—or mRNA—to tell our own cells what to do.

JORDAN: Okay, walk me through mRNA for a second. Why is it different from a normal shot?

ALEX: Think of DNA as your body’s master hard drive. mRNA is the temporary "instruction manual" that tells your cells which proteins to build. Normal vaccines put a piece of a dead virus into your arm to train your immune system.

JORDAN: Right, the old-school way. You show the immune system the "bad guy" and tell it to remember his face.

ALEX: Exactly. But Moderna wanted to send a digital instruction manual instead. They’d provide the code, and your own body would build the "bad guy" protein itself to practice the defense. You become your own drug factory.

JORDAN: It sounds brilliant, but I’m guessing the rest of the world wasn’t sold immediately.

ALEX: Not at all. For nearly a decade, Moderna was the "stealth startup." They raised billions of dollars but published very little peer-reviewed data. Critics, including Nobel laureates, called them a "black box" and questioned if the technology actually worked.

[CHAPTER 2 - Core Story]

JORDAN: So you’ve got a company worth billions with no products and a lot of skeptical scientists. What changed the game?

ALEX: The 2020 pandemic turned their unproven platform into the world's only hope for speed. Because they had spent ten years perfecting the delivery system—tiny fat bubbles called Lipid Nanoparticles—they were ready to go.

JORDAN: So when that genomic sequence hit the internet in January 2020, they didn't have to start from scratch?

ALEX: No. They basically just typed the new COVID-19 data into their existing software template. By February, they shipped the first batch of the vaccine to the NIH for testing. That is a process that usually takes years, and they did it in 25 days.

JORDAN: That is lightning fast. But did they just do this out of the goodness of their hearts, or was there some massive backing?

ALEX: Operation Warp Speed stepped in. The U.S. government poured about 2.5 billion dollars into Moderna's development and manufacturing. This allowed them to scale at a rate that would have been impossible for a company their size.

JORDAN: And the results were a knockout, right? I remember the headlines.

ALEX: 94.5% efficacy. It was a massive win for science. But as the money started rolling in—billions in profit—the honeymoon phase ended and the legal battles began.

JORDAN: Oh, I can smell the lawsuits coming. Who’s suing whom?

ALEX: Everyone. Moderna sued Pfizer and BioNTech, claiming they stole their mRNA blueprints. Meanwhile, the U.S. National Institutes of Health got into a public spat with Moderna because the company didn’t list government scientists as co-inventors on the key patent.

JORDAN: So the government funded the work, but Moderna wanted to keep the keys to the kingdom?

ALEX: Precisely. And then there’s the price. After the emergency ended, Moderna raised the price of the shot from roughly 16 dollars to over 110 dollars per dose. Critics called it profiteering off a public crisis.

[CHAPTER 3 - Why It Matters]

JORDAN: So, is Moderna just the "COVID vaccine company," or is this actually a new era of medicine?

ALEX: That’s the billion-dollar question. To prove they aren't a one-hit wonder, they just got their second product approved: an RSV vaccine for seniors. But the real prize is the rest of their pipeline.

JORDAN: What else can you treat with a digital instruction manual?

ALEX: They have 44 different candidates in the works. We’re talking vaccines for HIV, Zika, and even personalized cancer vaccines. They’re currently testing a way to take a biopsy of a patient’s tumor, sequence its DNA, and create a custom mRNA shot that tells that specific patient’s immune system to attack their specific cancer.

JORDAN: That would change everything. Instead of broad chemotherapy that kills everything in its path, you’re just giving the immune system a GPS coordinate for the tumor.

ALEX: Exactly. The legacy of Moderna isn't just about the pandemic; it's about the shift from slow, biology-based drug manufacturing to fast, digital-based drug programming.

[OUTRO]

JORDAN: It’s basically the App Store for our immune systems. What’s the one thing to remember about Moderna?

ALEX: Moderna proved that by treating the body's genetic code like software, we can design lifesaving medicine in days rather than decades.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Discover how a 1700s marine insurer transformed into a $195 billion healthcare titan through bold pivots, mega-mergers, and a controversial algorithm.

[INTRO]

ALEX: Imagine you’re in Philadelphia in 1792. Ships are sailing for Londonderry, and you’re the very first person in America to insure a vessel’s hull and cargo. Fast forward 230 years, and that same company is deciding whether or not to pay for your wisdom tooth extraction using an algorithm that takes 1.2 seconds.

JORDAN: Wait, from insuring wooden ships to 1-second dental reviews? That is a wild career change. We’re talking about Cigna, right?

ALEX: Exactly. Cigna didn't just grow; it fundamentally mutated from a colonial insurance company into a global health services powerhouse that brings in nearly 200 billion dollars a year.

JORDAN: But are they still an insurance company, or are they effectively a tech company that happens to handle our doctor bills?

[CHAPTER 1 - Origin]

ALEX: To understand Cigna, you have to look at its two parents. First, you have the Insurance Company of North America, or INA, founded in 1792. One of its founders was Robert Morris—a guy who literally signed the Declaration of Independence.

JORDAN: So Cigna has actual Founding Father DNA? That’s high-stakes starting point.

ALEX: It really is. On the other side, you have Connecticut General Life Insurance, born in 1865. For over a century, these two were the titans of the "Old Guard"—insuring lives, homes, and ships. Then, in 1982, they pulled off what was then the biggest merger in insurance history.

JORDAN: Let me guess. They took the 'CG' from Connecticut General and the 'INA' from the other guys?

ALEX: Precisely. They smashed them together to create the portmanteau "Cigna." But even then, they weren't the healthcare giant we know today. They were a massive, messy conglomerate selling everything from fire insurance to accident coverage.

JORDAN: So when did the pivot happen? When did they decide to stop caring about fire and start caring about our health?

ALEX: That was the 1990s. Under CEO Wilson Taylor, they realized the property and casualty market was too volatile. In a shocking move, they sold off their 200-year-old core business—the stuff that insured ships—to focus exclusively on healthcare and employee benefits. They essentially bet the entire house on the future of American wellness.

[CHAPTER 2 - Core Story]

JORDAN: So they've cleared the deck. They’re all-in on health. But the healthcare industry in the 2000s was basically a giant game of Hungry Hungry Hippos, right?

ALEX: It was survival of the biggest. Cigna tried to become the biggest by attempting a 54-billion-dollar merger with Anthem in 2015. It would have created the largest health insurer in U.S. history.

JORDAN: I remember this. Didn’t the government step in and say, "Absolutely not"?

ALEX: They did. The Department of Justice sued to block it, arguing it would kill competition. It got ugly, Jordan. Anthem and Cigna ended up in a years-long legal war, suing each other for billions after the deal collapsed. But instead of licking their wounds, Cigna’s current CEO, David Cordani, pivoted to a different strategy: vertical integration.

JORDAN: Meaning they didn't just want to be the one paying the bill; they wanted to be the one selling the medicine?

ALEX: Spotlight on 2018. Cigna drops 67 billion dollars to buy Express Scripts. This is a Pharmacy Benefit Manager, or PBM. Now, Cigna isn't just an insurer; they are the middleman negotiating drug prices and running the pharmacies that ship prescriptions to your door.

JORDAN: That sounds like a license to print money, but it also sounds like a massive conflict of interest. How does that sit with the public?

ALEX: Not well. It put them right in the crosshairs of the drug pricing debate. And then came the technology controversy. In 2023, a class-action lawsuit alleged Cigna used an algorithm called "PXDX" to mass-deny claims. The claim was that doctors spent an average of just 1.2 seconds per review.

JORDAN: 1.2 seconds? You can't even read a patient's name in 1.2 seconds!

ALEX: Cigna defended it, saying the tech helps with efficiency. But it highlights the core tension: when you’re this big, are you a partner in health, or are you a machine optimized to say "no"?

[CHAPTER 3 - Why It Matters]

JORDAN: So where does Cigna sit now? Are they the hero or the villain in the American healthcare story?

ALEX: It depends on who you ask. To investors, they are a masterpiece of integration. They’ve rebranded their health services arm as "Evernorth," which handles everything from telehealth to specialty pharmacies. They aren't just an insurance company anymore; they are a massive data and logistics firm.

JORDAN: But for the average person waiting for a claim approval, it feels like they’re just another giant corporation between you and your doctor.

ALEX: That’s the legacy. Cigna pioneered things like mental health coverage in the mid-20th century, but today they represent the "managed care" era—where every pill and procedure is a line item in a 195-billion-dollar spreadsheet. They’ve survived for two centuries by constantly changing their skin, and they’re betting that the future of medicine is more about algorithms and pharmacy logistics than it is about traditional insurance.

[OUTRO]

JORDAN: Okay, Alex, after 230 years of evolution, what’s the one thing we should remember about Cigna?

ALEX: Cigna is the ultimate corporate shapeshifter that moved from insuring 18th-century shipwrecks to controlling the 21st-century pharmacy through massive data and vertical integration.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Discover how a Minneapolis garage shop became a global medical giant, from the first battery-powered pacemaker to multi-billion dollar scandals.

[INTRO]

ALEX: In 1957, a massive power outage hit Minneapolis, and inside a local hospital, doctors realized with horror that their heart patients were literally plugged into the wall. If the grid went down, their hearts stopped.

JORDAN: Wait, so back then, a simple thunderstorm was basically a death sentence for anyone on a pacemaker?

ALEX: Exactly. But that crisis led a man named Earl Bakken to retreat to his garage and emerge with a device that changed humanity forever: the world's first wearable, battery-powered pacemaker. That was the birth of Medtronic, now the largest medical device company on Earth.

JORDAN: From a garage to a global titan? I’m guessing the journey from ‘saving lives’ to ‘billion-dollar corporation’ got a little complicated.

[CHAPTER 1 - Origin]

ALEX: It started as a humble repair shop in 1949. Earl Bakken was an electrical engineer who, along with his brother-in-law Palmer Hermundslie, spent their days fixing broken hospital equipment in Minnesota.

JORDAN: So they weren't even making their own tech yet? They were just the local 'tech support' for surgeons?

ALEX: Pretty much. But they were brilliant at it. The turning point came when Dr. C. Walton Lillehei, a pioneer in heart surgery, walked into their shop with a problem. He needed a way to keep his pediatric patients' hearts beating during recovery without being tethered to an unpredictable power grid.

JORDAN: And Bakken just... solved it? Just like that?

ALEX: He actually found the solution in a hobbyist magazine. He adapted a circuit design for a metronome from an issue of *Popular Electronics*. He built a prototype in four weeks, strapped it to a patient, and it worked.

JORDAN: It’s wild that a billion-dollar industry started with a transistorized metronome. What was the company culture like back then?

ALEX: Very mission-driven. In 1960, Bakken wrote the 'Medtronic Mission.' It’s a six-point pledge that places patient welfare and product quality above all else. To this day, employees still receive a medallion with this mission on it, but as the company grew into a multi-billion dollar behemoth, that mission would be put to some very public tests.

[CHAPTER 2 - Core Story]

ALEX: For decades, Medtronic was the undisputed king of innovation. They moved from external pacemakers to fully implantable ones, then into brain stimulators for Parkinson’s and pumps for diabetes. But in the 2000s, the company’s massive scale started to create massive friction.

JORDAN: Success usually brings a target on your back. What was the first big crack in the armor?

ALEX: It happened in 2007 with the Sprint Fidelis leads. These are the tiny wires that connect a defibrillator to the heart. They started fracturing inside patients’ bodies.

JORDAN: That sounds terrifying. If a wire breaks, the device either doesn't work when you're having a heart attack, or it shocks you for no reason, right?

ALEX: Both happened. Medtronic had to recall the product globally, affecting over a quarter-million people. But the real ethical storm hit a few years later with a product called Infuse, a bioengineered bone graft used in spinal surgeries.

JORDAN: I've heard of this. Wasn't there a scandal about the research being rigged?

ALEX: That’s exactly what *The Spine Journal* alleged in 2011. They claimed that Medtronic-funded studies systematically ignored side effects like nerve damage and sterility while making the product look like a miracle cure. It turned out the doctors writing these glowing reviews had received millions of dollars from Medtronic.

JORDAN: So much for that 'Mission Medallion.' Did they face any actual consequences?

ALEX: They paid out tens of millions in settlements, but the company kept growing. Their biggest move came in 2015 when they bought a company called Covidien for $43 billion. And that’s when they did something that made them a political villain in the US.

JORDAN: Let me guess: they moved their headquarters to avoid taxes?

ALEX: Spot on. It’s called a 'tax inversion.' They moved their legal home to Ireland to lower their tax bill, even though their actual operations stayed in Minnesota. US lawmakers called it 'corporate desertion,' but Medtronic argued it was the only way to stay competitive on a global stage.

[CHAPTER 3 - Why It Matters]

JORDAN: Despite the lawsuits and the tax drama, Medtronic is still the biggest player in the game. Why can't anyone knock them off the mountain?

ALEX: Because they’ve successfully transitioned from being just a hardware company to a 'health solutions' company. They aren't just selling you a pacemaker anymore; they’re selling a data-driven system that monitors your heart 24/7 and sends the data to your doctor’s iPad via the cloud.

JORDAN: So they're basically the 'Apple' of the human body now?

ALEX: That’s the goal. They’ve launched the Hugo robotic surgery system to compete with the famous da Vinci robots, and they've developed an 'artificial pancreas' for diabetics that automatically adjusts insulin levels using AI. They even made the world’s smallest pacemaker, which is roughly the size of a large vitamin pill.

JORDAN: It feels like they're moving toward a future where we’re all part-cyborg, and Medtronic owns the operating system.

ALEX: It’s a huge responsibility. When your product is literally inside someone’s heart or brain, there is zero room for error. Their current CEO, Geoff Martha, is trying to make the company leaner and more agile because, in the age of AI, a garage startup could disrupt them just like Bakken disrupted the big hospitals in the 50s.

[OUTRO]

JORDAN: Okay, Alex, after seventy years of history, what’s the one thing we should remember about Medtronic?

ALEX: Medtronic proves that while a company’s mission might start in a humble garage, its legacy is defined by how it balances life-saving innovation with the relentless pressure of global profit.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai.

Explore the evolution of Bristol-Myers Squibb, from Civil War medical purity to the high-stakes $74 billion gamble on the future of cancer treatment.

[INTRO]

ALEX: Imagine you're a Navy surgeon in the 1850s, and you realize the medicine you're giving your soldiers is essentially poison because there are no quality standards.

JORDAN: That sounds like a horror movie setup. Please tell me someone fixed it.

ALEX: One man did, and his obsession with purity eventually collided with two guys selling laxatives and hair dye to create Bristol-Myers Squibb—a company that now brings in 45 billion dollars a year by hacking the human immune system.

JORDAN: So we’re going from Civil War ether to multi-billion dollar cancer gambles? I’m in.

[CHAPTER 1 - Origin]

ALEX: The story starts with two very different souls. First, you have Dr. Edward Robinson Squibb. He was a man of total principle who founded E.R. Squibb & Sons in 1858 because he couldn't stand how adulterated drugs were back then.

JORDAN: He was the 'anti-snake oil' guy.

ALEX: Exactly. He invented a way to make pure ether for anesthesia and became the primary medical supplier for the Union Army during the Civil War. His brand was basically 'Quality at all costs.'

JORDAN: Noble, but usually, 'quality at all costs' doesn't lead to a 45-billion-dollar empire without a little marketing muscle.

ALEX: That’s where the other side comes in. In 1887, William Bristol and John Myers bought a failing drug company for five thousand bucks. They weren't crusaders; they were entrepreneurs who mastered the art of 'scientific advertising.'

JORDAN: Let me guess: they're the reason we have 'pink toothbrush' warnings and minty-fresh breath today?

ALEX: Precisely. They struck gold with Sal Hepatica—a laxative—and Ipana toothpaste. By the mid-20th century, they were a consumer goods machine, owning brands like Clairol hair dye and Enfamil baby formula.

[CHAPTER 2 - Core Story]

JORDAN: So you have the 'Pure Science' guys at Squibb and the 'Consumer Marketing' guys at Bristol-Myers. How do they end up in one boardroom?

ALEX: It happened in 1989. It was a 12.7 billion dollar 'merger of equals'—the largest in pharma history at the time. They wanted to create a global powerhouse that could combine Squibb’s research on heart drugs with Bristol-Myers’ massive marketing machine.

JORDAN: But mergers that big usually mean someone has to lose an identity. Did they stay a toothpaste company or a drug company?

ALEX: For a while, they were both, but then the world changed. In the early 2000s, they hit what the industry calls the 'patent cliff.' Their biggest money-makers, like the blood thinner Plavix, were losing their patent protection.

JORDAN: Meaning generic versions flood the market and the profits disappear overnight. That’s a death sentence if you don't have a plan B.

ALEX: Their plan B was a total pivot. They sold off Clairol to Proctor & Gamble, spun off the baby formula, and bet the entire company on 'biopharmaceuticals.'

JORDAN: That sounds like fancy talk for 'really expensive specialized drugs.'

ALEX: It is. Specifically, they went all-in on immuno-oncology. They developed drugs like Opdivo and Yervoy. Instead of using chemicals to kill cancer cells, these drugs essentially 'unmask' the cancer so your own immune system can see it and attack it.

JORDAN: That’s a huge scientific leap. But I bet those drugs aren't cheap.

ALEX: Not at all. We’re talking 150,000 dollars a year or more. This pivot led to their biggest move yet in 2019: buying Celgene for 74 billion dollars.

JORDAN: Seventy-four billion? That is a staggering amount of debt to take on just to stay at the top of the mountain.

ALEX: It was a massive gamble. They bought Celgene specifically for their blood cancer treatments, knowing they needed new blockbusters to replace the ones that were about to go generic. It turned them into a pure-play medical giant, leaving the hair dye and laxatives far in the past.

[CHAPTER 3 - Why It Matters]

JORDAN: So, they’ve successfully transitioned from selling toothpaste to high-tech immune system hacks. Why should we care about this specific corporate evolution?

ALEX: Because BMS essentially pioneered the model for how modern drug companies operate. They proved that you can’t be a 'jack of all trades' anymore. To survive, you have to be a specialist in the most difficult diseases.

JORDAN: But does that specialization come at a cost to the rest of us?

ALEX: It’s the ultimate tension of the industry. On one hand, they’ve turned metastatic melanoma—which used to be a death sentence—into a manageable condition for many people. They’ve saved countless lives with their blood thinners.

JORDAN: And on the other hand?

ALEX: On the other hand, they’ve faced massive settlements for 'off-label' marketing and constant criticism over drug pricing. They are the poster child for the 'innovator’s dilemma': the science is miraculous, but the economics are brutal.

[OUTRO]

JORDAN: Alright Alex, if I'm at a dinner party and someone mentions Big Pharma, what's the one thing I should remember about Bristol-Myers Squibb?

ALEX: Remember that they are the company that abandoned consumer products to bet 74 billion dollars on the idea that the future of medicine isn't in a pill bottle, but inside our own immune systems.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Explore how a Minneapolis garage startup invented the first battery-powered pacemaker and grew into a global medical giant amid tax controversies and recalls.

[INTRO]

ALEX: In 1957, a massive power outage hit Minneapolis, and in the local hospital, children relying on plug-in heart pacemakers were suddenly in mortal danger. That crisis led a man named Earl Bakken to retreat to his garage and, in just four weeks, invent the world’s first wearable, battery-powered pacemaker using a circuit design he found in a hobbyist magazine.

JORDAN: Wait, so the foundation of a multi-billion-dollar medical empire started with a guy basically DIY-ing a life-saving device in his garage? That sounds terrifyingly unofficial.

ALEX: It was the birth of an entire industry. Today, Medtronic is the largest medical device company on the planet, with more than 90,000 employees, but that tension—between the "garage inventor" spirit and the realities of a global corporation—is exactly what we’re diving into today.

[CHAPTER 1 - Origin]

ALEX: Before the pacemaker, Medtronic was just a struggling repair shop for medical equipment, founded in 1949 by Bakken and his brother-in-law, Palmer Hermundslie. They weren't making much money; they were mostly fixing broken hospital gear until they met Dr. C. Walton Lillehei, a pioneer in open-heart surgery.

JORDAN: Let me guess, Lillehei was the one who lost a patient during that power outage?

ALEX: Exactly. He asked Bakken if there was a way to keep a heart beating without a wall outlet. Bakken took a metronome circuit—the kind musicians use to keep time—and modified it to send electrical pulses to the heart.

JORDAN: So, the first pacemaker was essentially a glorified metronome?

ALEX: In principle, yes. He tested it on a dog, and the next day, it was used on a three-year-old girl named Susie Bleything. It worked. She lived to be 75. That success changed Medtronic from a repair shop into a visionary manufacturer almost overnight.

JORDAN: I’m assuming the medical world didn't just stay in the garage for long. How did they go from one guy with a soldering iron to 150 countries?

ALEX: Bakken wasn't just an engineer; he was an ethicist. In 1960, he wrote the "Medtronic Mission," a document that is still recited by employees today. It focused on restoring health and extending life, which gave the company a soul even as it started expanding into neurostimulation, spinal implants, and diabetes care.

[CHAPTER 2 - Core Story]

ALEX: For decades, Medtronic was the gold standard, releasing the first commercial implantable defibrillators and the world's smallest pacemakers. But as they grew, the "mission" started to collide with the "margin." The 2000s and 2010s turned into a roller coaster of massive acquisitions and public scandals.

JORDAN: This is usually where the "big corporate" stuff ruins the feel-good story, right? What happened?

ALEX: The turning point was 2015. Medtronic spent nearly $43 billion to buy a company called Covidien. On paper, it broadened their surgical portfolio, but the real headline was that the deal was a "corporate inversion."

JORDAN: Explain that like I’m not an accountant.

ALEX: Basically, Medtronic moved its legal headquarters to Ireland to take advantage of lower tax rates and access billions in cash they had sitting offshore. Critics called it a tax dodge that cost the U.S. Treasury upwards of $10 billion. Suddenly, the company that started in a Minneapolis garage didn't want to be an "American" company anymore, at least not for tax purposes.

JORDAN: Ouch. Patriotism aside, were the products still working? Because that's what really matters for a medical company.

ALEX: That’s where things got even more complicated. In 2007, they had to recall a massive number of "Sprint Fidelis" heart leads—the wires that connect the device to the heart. They were fracturing, which meant patients were either getting no help or, worse, getting hit with massive, unnecessary electric shocks.

JORDAN: That sounds like a nightmare. If my life depends on a piece of tech, I need it to be more than just "mostly" reliable.

ALEX: It gets worse in the digital age. In 2019, the FDA warned that some of Medtronic’s insulin pumps were vulnerable to hackers. Someone could theoretically remotely change a patient’s insulin dose. They’ve also paid out millions to settle allegations of paying kickbacks to doctors to use their spinal products.

JORDAN: So they went from saving a three-year-old girl with a metronome to fighting off hackers and federal investigators? That is a wild arc.

[CHAPTER 3 - Why It Matters]

ALEX: It is, but despite the controversies, Medtronic is still the engine of modern medicine. If you or someone you know has a pacemaker, a stent, an insulin pump, or a spinal implant, there’s a massive chance it has a Medtronic logo on it. They are currently pivoting into robotic-assisted surgery and AI-driven data to predict health crises before they happen.

JORDAN: It seems like they’re trying to move from being just a hardware company to being the literal operating system of the human body.

ALEX: That's the goal. Their new CEO, Geoff Martha, is pushing into high-tech areas like the Hugo robot to compete with other tech giants. They even open-sourced their ventilator designs during the COVID-19 pandemic to help with the global shortage, which felt like a return to that original 1960 mission.

JORDAN: It’s a strange balance. They’re a tax-minimizing, acquisition-hungry machine that also happens to be the reason millions of people are still breathing.

[OUTRO]

JORDAN: Alright Alex, if I’m at a dinner party and Medtronic comes up—unlikely, but stay with me—what’s the one thing I need to remember about them?

ALEX: Remember that the entire multi-billion dollar medical device industry exists because one engineer in a garage realized he could keep a heart beating using the same technology as a musician’s metronome.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai

Explore how a small 1960s beauty shop transformed into CVS Health, a global giant controlling everything from your insurance to your local pharmacy.

[INTRO]

ALEX: Most people think of CVS as the place where you buy greeting cards and get receipts long enough to wallpaper a room. But here is the reality: CVS Health is actually the second-largest healthcare company on the planet.

JORDAN: Wait, the second largest? When did the corner drugstore start running the entire medical system?

ALEX: It didn’t happen overnight, but today they own your local pharmacy, the company that manages your insurance benefits, and the insurance provider itself. They’ve basically built a closed-loop system where they are the doctor, the pharmacist, and the bill collector.

[CHAPTER 1 - Origin]

ALEX: This all started in 1963 in Lowell, Massachusetts. Two brothers, Stanley and Sidney Goldstein, teamed up with a partner named Ralph Hoagland to open a shop called Consumer Value Stores.

JORDAN: Consumer Value Stores... so that’s what CVS actually stands for? It sounds more like a dollar store than a medical giant.

ALEX: Exactly. At first, they didn't even sell medicine; they sold health and beauty products. They didn’t even open their first pharmacy department until a year later, in Rhode Island.

JORDAN: So how does a discount beauty shop in New England end up ranking 64th on the Forbes Global 2000?

ALEX: They had a very powerful parent company early on called Melville Corporation. Melville gave them the capital to swallow up rivals. By the mid-70s, they were doing a hundred million in sales, and by the 90s, they were ready to break off on their own and start a shopping spree that would change American healthcare forever.

[CHAPTER 2 - Core Story]

ALEX: In the late 90s, CVS decided that being just a pharmacy wasn't enough. They bought over 2,500 Revco stores in one go, nearly doubling their size. But the real shift happened in 2006 when they bought MinuteClinic.

JORDAN: I remember those. It was the first time you could walk into a store and see a nurse practitioner for a sinus infection instead of waiting three weeks for a doctor.

ALEX: That was the hook. They wanted to become the "front door" of healthcare. But the biggest move came in 2007 when they merged with Caremark Rx for 21 billion dollars.

JORDAN: I’ve seen Caremark on my insurance card, but what do they actually do?

ALEX: They are a PBM—a Pharmacy Benefits Manager. They are the middlemen who negotiate drug prices between manufacturers and insurance companies. By owning Caremark, CVS wasn't just selling the drugs; they were now the ones deciding which drugs your insurance would actually cover.

JORDAN: That sounds like a massive conflict of interest. Does the store benefit if I buy the drugs they manage?

ALEX: That is the exact question critics ask. And CVS didn't stop there. In 2014, they made a massive PR move by banning all tobacco sales in their stores. They rebranded as "CVS Health" and walked away from two billion dollars in annual cigarette revenue to prove they were serious about wellness.

JORDAN: That’s a lot of money to leave on the table. It makes them look like the good guys, right?

ALEX: It certainly helped their image for the biggest swing of all. In 2018, they bought Aetna, one of the largest health insurers in America, for 69 billion dollars. Now, the circle was complete: they provide the insurance, they manage the drug benefits, and they own the pharmacy where you pick up the prescription.

[CHAPTER 3 - Why It Matters]

JORDAN: Okay, so they own the whole pipeline. But why should the average person care if their insurer and their pharmacist have the same logo on their paycheck?

ALEX: Because it changes the economics of your medicine. For example, a 2018 audit in Ohio found that PBMs—including Caremark—charged the state's Medicaid program 223 million dollars more than they actually paid the pharmacies for generic drugs. They pocket the difference, which is known as "spread pricing."

JORDAN: So the middleman is essentially marking up the price and keeping the change?

ALEX: That’s the allegation. And while they’re facing lawsuits over their role in the opioid crisis—paying out five billion dollars in settlements—they’re also moving deeper into your home. Under their current CEO, Karen Lynch, they’ve spent nearly 20 billion dollars buying Signify Health and Oak Street Health.

JORDAN: What do those companies do?

ALEX: Signify does in-home health visits, and Oak Street is a primary care network. CVS isn't just the store on the corner anymore; they want to be the doctor in your living room. They are betting that by controlling every single step of the process, they can manage costs better than anyone else.

JORDAN: Or they just become so big that you don't have a choice but to use them.

ALEX: That is the multi-billion dollar tension. They are closing hundreds of stores to focus on these "HealthHUBs," but in doing so, they are creating "pharmacy deserts" in poor neighborhoods where people rely on those local branches.

[OUTRO]

JORDAN: It’s wild to think my local pharmacy is actually a massive insurance and data company. What’s the one thing to remember about CVS Health?

ALEX: CVS has transformed from a simple retail store into a vertically integrated giant that manages your insurance, your prescriptions, and your primary care all under one corporate roof.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai.

Explore the rise, fall, and restructuring of Citigroup, from its 1812 origins to its role as the poster child for 'too big to fail.'

[INTRO]

ALEX: In 1977, a bank in New York made a promise that changed how every person on Earth interacts with their money: they pledged to put an automated teller machine on every single corner of the city.

JORDAN: Wait, are you saying one bank basically invented the 24/7 ATM lifestyle?

ALEX: Exactly. That bank was Citibank, and they even coined the iconic slogan "The Citi Never Sleeps" to prove it.

JORDAN: It’s a great line, but I’ve seen the headlines. That lack of sleep eventually led to some pretty massive financial nightmares, didn't it?

ALEX: It absolutely did. Today we’re looking at Citigroup—a bank that grew so big it legally forced the U.S. government to change its laws, only to face a collapse so spectacular it nearly took the global economy down with it.

[CHAPTER 1 - Origin]

ALEX: To understand the ego of Citigroup, you have to go back to 1812. It started as the City Bank of New York, founded by a group of merchants who immediately began financing the War of 1812 against Great Britain.

JORDAN: So they were playing at the highest level of geopolitics from day one? Not exactly a local credit union.

ALEX: Not at all. By the early 1900s, under a visionary named Frank Vanderlip, they became the first American bank to open a branch overseas, specifically in Buenos Aires in 1914. Vanderlip boasted that the American dollar would become the international standard, and he used City Bank to make it happen.

JORDAN: He was calling the shots for the entire U.S. dollar? That’s some serious confidence.

ALEX: It set a pattern of "firsts." They hired the first female officer on Wall Street, Sylvia Porter, in the 30s. They financed the Panama Canal. But the real transformation happened in the 60s and 70s under CEO Walter Wriston.

JORDAN: Is he the ATM guy?

ALEX: He’s the architect of modern banking. He didn't just want a bank; he wanted a global technology company that handled money. He pushed credit cards—which they called "The Everything Card"—and spent billions on computer systems while other banks were still using ledger books.

JORDAN: So they were the Apple of banking? Disrupting everything?

ALEX: Precisely. But there was a catch. Since the Great Depression, the Glass-Steagall Act had prevented banks from being both a regular commercial bank and a risky investment bank. Wriston and his successors hated that wall, and they spent decades looking for a sledgehammer to knock it down.

[CHAPTER 2 - Core Story]

ALEX: That sledgehammer arrived in 1998 in the form of a man named Sandy Weill. He was the CEO of Travelers Group, a massive insurance and investment firm, and he proposed a 70-billion-dollar merger with Citicorp.

JORDAN: But wait, if Glass-Steagall was still law, wasn't a merger between a bank and an insurance giant illegal?

ALEX: It was technically illegal at the time. But Weill and Citicorp CEO John Reed did it anyway. They announced the merger and basically dared Congress to stop them, banking on the idea that they were creating a "financial supermarket" that would benefit everyone.

JORDAN: That’s incredibly bold. Did the government actually cave?

ALEX: They did. A year later, Congress passed the Gramm-Leach-Bliley Act, which repealed the old restrictions and retroactively blessed the birth of Citigroup. Sandy Weill had his empire: you could get your checking account, your home insurance, and your stock portfolio all under one red umbrella.

JORDAN: It sounds convenient, but also like a lot of eggs in one very large and complicated basket.

ALEX: And that basket had holes. By 2008, Citigroup’s complexity became its curse. They had loaded up on billions of dollars in subprime mortgage-backed securities—assets that were essentially ticking time bombs. When the housing market crashed, the "financial supermarket" caught fire.

JORDAN: How bad did it get? Were they actually going under?

ALEX: They were on the brink of total evaporation. To prevent a global meltdown, the U.S. government staged a massive intervention. They injected 45 billion dollars in cash and guaranteed over 300 billion dollars’ worth of the bank's risky assets. At one point, the American taxpayer essentially owned 36 percent of Citigroup.

JORDAN: So the bank that wanted to be more powerful than the law ended up being subsidized by the people who live under those laws.

ALEX: Exactly. And the drama didn't end with the bailout. The next decade was a parade of fines. They paid 7 billion for toxic mortgages, hundreds of millions for manipulating interest rates, and almost a billion for colluding on currency markets.

JORDAN: It sounds like the bank was just too big to control itself.

ALEX: That’s the consensus. In 2020, they even had a world-class facepalm moment called the "Revlon Error." A Citibank employee accidentally wired 900 million dollars of the bank's own money to Revlon’s lenders.

JORDAN: 900 million? By accident? I feel bad when I Venmo the wrong person twenty bucks!

ALEX: It was a massive embarrassment that proved their internal systems were still a mess years after the crisis.

[CHAPTER 3 - Why It Matters]

JORDAN: So where does that leave them today? Is the "supermarket" still open for business?

ALEX: Under their current CEO, Jane Fraser—the first woman to lead a major U.S. bank—the strategy has completely flipped. She’s essentially dismantling Sandy Weill’s dream. She is exiting consumer banking in dozens of international markets and focusing the bank on what it does best: helping massive corporations and the ultra-wealthy move money.

JORDAN: So they're finally admitting that being everything to everyone was a mistake?

ALEX: They’re trying to become "smaller and simpler," which are two words you never used to hear in the same sentence as Citigroup. They are the ultimate case study in the dangers of complexity. They proved that if a bank is too big to fail, it might also be too big to manage.

JORDAN: It’s a long way from the bank that financed the War of 1812.

ALEX: It is. They’ve spent two centuries trying to conquer the financial world, and now they’re spending billions just trying to make sure they don’t accidentally wire a billion dollars to the wrong person again.

[OUTRO]

JORDAN: Alex, what’s the one thing to remember about Citigroup?

ALEX: Citigroup is the institution that broke the rules of American banking to become a global giant, only to prove that extreme size creates risks that no bailout can truly fix.

JORDAN: That’s Wikipodia — every story, on demand.

ALEX: Search your next topic at wikipodia.ai.